UB-VV500 with rapamycin for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an investigational cell therapy called UB-VV500 combined with rapamycin, a drug that may help the therapy work better. It is for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You have multiple myeloma that has come back or not responded to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
- You must have measurable disease (signs of cancer that can be detected and tracked).
- You must be in generally good health, aside from the cancer, with no serious untreated infections or other major health problems.
- You must have a performance status of 0 or 1 (meaning you are fully active or able to do light work).
- You must not have certain other plasma cell disorders or conditions like plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or AL amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for people with multiple myeloma that has come back or hasn't improved with other treatments. It aims to see if the therapy can help control the disease.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests an experimental treatment called UB-VV400 given with another drug, rapamycin, for people with large B-cell lymphoma that has not responded to standard therapy. The treatment targets a protein called CD22 on lymphoma cells and may help your immune system fight the cancer.
This trial tests a new combination therapy (UB-VV400 plus rapamycin) for people with B-cell cancers that have come back or not responded to previous treatment. It aims to see if this approach is safe and effective.
This trial tests a new therapy called UB-VV111, alone or with rapamycin, in people with certain types of lymphoma or leukemia that have come back or not responded to treatment. The goal is to see if it's safe and effective.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.